Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.

• ClinicalTrials.gov Identifier: NCT02457247
• Recruitment Status: Completed
• First Posted: May 29, 2015
• Results First Posted: October 25, 2016
• Last Update Posted: October 25, 2016
• Sponsor: Takeda
• Information provided by (Responsible Party): Takeda

Study Description

Brief Summary:

The purpose of this study is to compare the preference of Calcichew D3 500/400 (containing 500 mg calcium and 400 IU of vitamin D) with Adcal-D3 600/400 (containing 600 mg of calcium and 400 IU of vitamin D) in Test Group 1, and to compare Calcichew D3 500/800 (containing 500 mg calcium and 800 IU vitamin D) with Kalcipos-D 500/800 (containing 500 mg of calcium and 800 IU of vitamin D) in Test Group 2.

Condition or disease	Intervention/treatment	Phase
Calcium and Vitamin D Deficiencies	Drug: Calcichew D3; Drug: Adcal-D3; Drug: Kalcipos-D	Phase 4

Detailed Description:

The drug being tested in this study is called Calcichew D3 new formulations: Calcichew D3 500/400 and Calcichew D3 500/800. Calcichew D3 500/400 and Calcichew D3 500/800 are being tested to treat or prevent calcium or vitamin D deficiencies. Calcichew D3 500/400 will be compared to Adcal-D3 600/400 as prescribed in clinical practice and Calcichew D3 500/800 will be compared to Kalcipos-D 500/800 as prescribed in clinical practice.

This Crossover study will enroll approximately 276 patients equally divided between the two test groups (138 patients each). Within each test group, participants will be randomly assigned (by chance, like flipping a coin) to one of two treatment sequences, as described below.

Test Group 1:

• Calcichew D3 500/400 (containing 500 mg calcium and 400 IU of vitamin D) chewable tablet
• Adcal-D3 600/400 (containing 600 mg of calcium and 400 IU of vitamin D) chewable tablet

Test Group 2:

• Calcichew D3 500/800 (containing 500 mg calcium and 800 IU vitamin D) chewable tablets
• Kalcipos-D 500/800 (containing 500 mg of calcium and 800 IU of vitamin D) chewable tablets

Participants in Test Group 1 will take either Calcichew D3 500/400 or Adcal-D3 600/400 for 14 days and then will crossover to take either Calcichew D3 500/400 or Adcal-D3 600/400 treatment for 14 days. Participants in Test Group 2 will take either Calcichew D3 500/800 or Kalcipos-D 600/400 for 14 days and then will crossover to take either Calcichew D3 500/800 or Kalcipos-D treatment for 14 days.

This multi-center trial will be conducted In the United Kingdom and Germany. The overall time to participate in this study is 28 days. Participants will make multiple visits to the clinic including a final visit assessment at Day 28.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 276 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-Label, 2-Way Cross-Over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D Supplementation
• Study Start Date: June 2015
• Actual Primary Completion Date: August 2015
• Actual Study Completion Date: August 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Test Group 1: Sequence AB; Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.	Drug: Calcichew D3; Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3); Drug: Adcal-D3; Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
Experimental: Test Group 1: Sequence BA; Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.	Drug: Calcichew D3; Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3); Drug: Adcal-D3; Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
Experimental: Test Group 2: Sequence CD; Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.	Drug: Calcichew D3; Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3); Drug: Kalcipos-D; Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
Experimental: Test Group 2: Sequence DC; Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.	Drug: Calcichew D3; Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3); Drug: Kalcipos-D; Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With a Preference for Each Treatment Within Each Test Group [ Time Frame: Day 28 ]
   Preference was assessed by a 3 box questionnaire. Participants checked off one of the boxes: I prefer the first product that was tested, I prefer the second product that was tested or I have no preference. Test Group 1 (United Kingdom): Calcichew D3 is 500/400 and the comparator is Adcal-D3. Test Group 2 (Germany): Calcichew D3 is 500/800 and the comparator is Kalcipos-D.

Secondary Outcome Measures :

1. Product Acceptability After Each 14 Day Dosing Period Within Each Test Group [ Time Frame: Day 14 and Day 28 ]
   Product acceptability was assessed by a 6 item questionnaire evaluating the characteristics of the product: gritty, chalky, sweet, ease of chew, ease of swallow and sticky. Using a 100 mm visual analog scale (VAS) the participant put a vertical line through each horizontal line that best describes their level of agreement with each item using a 0 to 100 scale where: 0=far left of the line (best) to 100= far right of the line (worst). Linear mixed model was used for analysis with treatment and period as fixed effects and participants as a random effect.
2. Product Tolerability Expressed as the Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event Within Each Test Group [ Time Frame: Day 1 to Day 28 ]
   An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
2. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. Is eligible for or currently receiving treatment with calcium and vitamin D supplement as determined by the treating clinician in accordance with local treatment guidelines.

4. Eligible participants will either be:

   1. Aged 65 years or older requiring calcium and vitamin D supplementation for the prevention or treatment of deficiencies, or
   2. Aged 18 years or older that require calcium and vitamin D as an adjunct to specific osteoporosis treatment in participants at risk of calcium and vitamin D deficiencies.
5. Is male or female.
6. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study, and for 12 weeks after last dose of study medication.

Exclusion Criteria:

1. Has received Calcichew D3, Adcal-D3 (if the participant is in Test Group 1) or Kalcipos-D (if the participant is in Test Group 2) within the 6 months prior to the first dose of study medication.
2. Has received any investigational compound within 30 days prior to Screening.
3. Has a disease and/or condition resulting in hypercalcaemia and/or hypercalciuria and for which the study drugs are contraindicated e.g. Zollinger-Ellison syndrome, nephrolithiasis.
4. Has any of the contraindications listed in the corresponding Summary of Product Characteristics (SPC) of the study drug that the participant may receive depending on the Test Group: Calcichew D3 or Adcal-D3 (if the participant is in Test Group 1); Calcichew D3 or Kalcipos-D (if the participant is in Test Group 2).
5. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
6. Has a history of hypersensitivity or allergies to the active substances or to any of the excipients in the investigational products.
7. Has a history of known fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
8. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 12 weeks after participating in this study; or intending to donate ova during such time period.

Contacts and Locations

Locations

Germany

Berlin, Germany

Bochum, Germany

Frankfurt, Germany

Leipzig, Germany

United Kingdom

Reading, Berkshire, United Kingdom

Birmingham, United Kingdom

Chorley, United Kingdom

Liverpool, United Kingdom

Manchester, United Kingdom

Sponsors and Collaborators

Takeda

Investigators

• Study Director: Medical Director Clinical Science; Takeda

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Thomasius F, Keung Nip T, Ivan P. Phase IV randomized preference study in patients eligible for calcium and vitamin D supplementation. Curr Med Res Opin. 2016 Oct;32(10):1623-1631. doi: 10.1080/03007995.2016.1202817. Epub 2016 Jun 29.

• Responsible Party: Takeda
• ClinicalTrials.gov Identifier: NCT02457247
• Other Study ID Numbers: Calcichew-4001; 2014-005619-18 ( EudraCT Number ); U1111-1166-8818 ( Registry Identifier: WHO ); 15/NW/0275 ( Registry Identifier: NRES )
• First Posted: May 29, 2015
• Results First Posted: October 25, 2016
• Last Update Posted: October 25, 2016
• Last Verified: August 2016

Keywords provided by Takeda:

Drug therapy

Additional relevant MeSH terms:

Vitamin D Deficiency; Avitaminosis; Deficiency Diseases; Malnutrition; Nutrition Disorders; Calcium Carbonate; Antacids; Molecular Mechanisms of Pharmacological Action; Gastrointestinal Agents